French recommendations on strategies for preventing and treating osteoporosis induced by adjuvant breast cancer therapies
| Autor: | Rose-Marie Javier, Béatrice Bouvard, Christophe Hennequin, Didier Mayeur, Jean-Michel Hannoun-Levi, Eric Lespessailles, Florence Trémollières, Cyrille B. Confavreux, Catherine Cormier, Bernard Cortet, Françoise Debiais, Pierre Kerbrat, A. Lesur, Julien Paccou, Jacques Bonneterre, Marie-Hélène Vieillard, Karine Briot |
|---|---|
| Přispěvatelé: | Imagerie Multimodale Multiéchelle et Modélisation du Tissu Osseux et articulaire (I3MTO), Université d'Orléans (UO) |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.drug_class medicine.medical_treatment Osteoporosis Breast Neoplasms 03 medical and health sciences 0302 clinical medicine Breast cancer Adjuvants Immunologic Rheumatology Bone Density Internal medicine medicine Humans 030212 general & internal medicine Medical prescription ComputingMilieux_MISCELLANEOUS 030203 arthritis & rheumatology Chemotherapy Aromatase inhibitor business.industry Incidence medicine.disease 3. Good health Denosumab [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system Chemotherapy Adjuvant Practice Guidelines as Topic Female Amenorrhea France Hormone therapy medicine.symptom business medicine.drug |
| Zdroj: | Joint Bone Spine Joint Bone Spine, Elsevier Masson, 2019, 86 (5), pp.542-553. ⟨10.1016/j.jbspin.2019.07.005⟩ |
| ISSN: | 1297-319X |
| DOI: | 10.1016/j.jbspin.2019.07.005 |
| Popis: | Standard adjuvant therapies for breast cancer such as chemotherapy or aromatase inhibitor and LH-RH agonist hormone therapy are associated with significant survival gains but also induce bone loss by aggravating the estrogen deprivation. The bone loss may be substantial, notably during early treatment, and occurs regardless of the baseline bone mineral density values. The objective of developing these recommendations was to achieve a practical consensus among various scientific societies, based on literature review, about osteoporosis prevention and treatment in these patients. The following scientific societies contributed to the work: Société Française de Rhumatologie (SFR), Groupe de Recherche et d'Information sur les Ostéoporoses (GRIO), Groupe Européen d'Etudes des Métastases Osseuses (GEMO), Association Francophone pour les Soins Oncologiques de Support (AFSOS), Société Française de Sénologie et de Pathologie Mammaire (SFSPM), Société Française de Radiothérapie Oncologique (SFRO). Drug prescription and reimbursement modalities in France were taken into account. These recommendations apply to postmenopausal women taking systemic chemotherapy and/or aromatase inhibitor therapy, non-postmenopausal women taking LH-RH agonist therapy, and non-postmenopausal women with persistent amenorrhea 1 year after chemotherapy completion. All women in these three categories should undergo an evaluation of bone health and receive interventions to combat risk factors for bone loss. Patients with a history of severe osteoporotic fracture and/or a T-score value-2.5 should receive osteoporosis drug therapy. The FRAX® score should be used to guide treatment decisions in patients whose T-score is between -1 and -2.5. General osteoporosis prevention measures should be applied in patients without criteria for osteoporosis drug therapy, who should undergo bone mineral density measurements 18-24 months later if the baseline T-score is-1 and 3-5 years later if the baseline T-score is-1. The anti-tumor effect of bisphosphonates and denosumab was not considered when establishing these recommendations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect